A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
about
Current and emerging therapies in unresectable and recurrent gastric cancerClinical significance of MET in gastric cancerOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerA unified model of the hierarchical and stochastic theories of gastric cancer.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.Comparative proteomics analysis of gastric cancer stem cells.Recent advances in the HER2 targeted therapy of gastric cancerLong noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cellsSorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells.Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis.LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET.Role of Recepteur D'origine Nantais on Gastric Cancer Development and ProgressionIn vitro and in vivo effects of miRNA-19b/20a/92a on gastric cancer stem cells and the related mechanism.LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.Biomarkers of gastric cancer: Current topics and future perspective
P2860
Q26745453-879BF3EF-563E-40B4-A88C-A323ECBEC9A6Q26776190-F3A7B300-D9A1-49FF-89B5-9A5B91E7481EQ28067777-98519F82-01A6-468C-B4C8-C8A9E7FED006Q33577624-D26030AE-582C-43B4-BF94-98139A0D5A4DQ33917507-1EB3F74D-18AF-42B9-A54F-6E281CA4CDE4Q34309903-19BFCF82-6393-401E-B5C1-BC65F98C11C0Q34472812-EF9B16DF-52E9-41CC-A838-70989F7CDB64Q34967104-00C5B624-9F03-4EBE-BD8F-1A59945DE70BQ35585395-A15E18F7-A108-49E7-B102-4C0EE2C4794BQ35828564-6C0149B0-6261-4A3A-ADCC-16808AECFE70Q36689033-D501D4BF-F1AA-403E-BD37-E1131437D2E8Q37472110-FDB6A175-AB37-4FB1-B8C8-DB301C67C4EAQ38263575-25A453AD-B925-46CF-B041-4B7AF4F56FDDQ38393333-C927E87C-1D37-4372-81CD-CC043C2BF49BQ38708140-086BB904-DB0B-41EF-B0F0-AAC48C187D02Q38710661-5F5D2468-220E-44B7-8845-FB28AADE7A26Q38913406-D195FD1D-9B18-41F7-8991-53D1FA26BA9EQ42262007-AF03C15A-460E-4A1D-A3A6-AF6DA32026A9Q49321970-0CF6621D-40B3-47AF-B932-2251A4285904Q50094397-D550C990-7E1D-451A-9002-934F44E37193Q57176090-4D895956-DC4C-4B23-AF42-A8B6DB45DA58
P2860
A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@en
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@nl
type
label
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@en
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@nl
prefLabel
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@en
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@nl
P2093
P2860
P356
P1476
A c-Met inhibitor increases th ...... inotecan in gastric carcinoma.
@en
P2093
K Hirakawa
T Hasegawa
T Matsuzaki
T Morisaki
P2860
P2888
P304
P356
10.1038/BJC.2013.638
P407
P577
2013-10-15T00:00:00Z